| Table 1. General characteristics of the study population | ||||
|
General population (n=129) |
GnRH agonist protocol (n=73) |
GnRH antagonist protocol (n=56) |
P | |
| Age (years) |
34.5±4.8 (21-39) |
34.6±5.2 (21-39) |
34.3±4.3 (26-39) |
0.70 |
| AMH (ng/ml) |
1.8±1.8 (0.01-9.6) |
1.5±1.3 (0.01-8.2) |
2.1±2.1 (0.01-9.6) |
0.33 |
| AFC (n) (2-9 mm) |
12.1±6.0 (2-34) |
11.4±5.3 (2-34) |
13.1±6.7 (4-28) |
0.24 |
| ORPI |
1.0±1.4 (0-8.8) |
0.7±1.1 (0-8.8) |
1.2±1.7 (0-7.6) |
0.30 |
| BMI | 24.4±4.6 | 24.0±5.0 | 25.1±3.9 | 0.19 |
| Tobacco use | 3.9% (5/129) | 2.7% (2/73) | 5.3% (3/56) | 0.76 |
| Regular alcohol use | 2.3% (3/129) | 1.4% (1/73) | 3.6%(2/56) | 0.81 |
| Time of infertility (years) | 4.7±3.6 | 5.1±4.0 | 4.1±2.8 | 0.14 |
|
Aetiology (%) Male Idiopathic Tuboperitoneal Endometriosis Tuboperitoneal+endometriosis Male+endometriosis Male+tuboperitoneal |
36.4%(47/129) 26.4% (34/129) 17.8% (23/129) 13.2% (17/129) 3.1% (4/129) 2.3% (3/129) 0.8% (1/129) |
41.1% (30/73) 20.5% (15/73) 17.8% (13/73) 15.1% (11/73) 2.7% (2/73) 1.4% (1/73) 1.4% (1/73) |
30.4% (17/86) 33.3% (19/56) 17.8% (10/56) 10.7% (6/56) 3.6% (2/56) 3.6% (2/56) 0 (0/56) |
0.26 |
| Total dose FSH (UI) | 1983±806 | 2106±768 | 1743±796 | 0.34 |
| Total dose LH (UI) | 989±343 | 1014±316 | 956±376 | 0.60 |
| Time of stimulation (days) | 10.0±2.1 | 10.4±2.1 | 9.5±1.9 | 0.21 |
|
Follicles (n) (hCG day) ≥10 mm ≥16 mm ≥18 mm |
12.4±8.3 5.7±3.5 3.8±2.5 |
12.3±7.3 6.2±3.6 4.1±2.3 |
12.5±9.5 4.9±3.4 3.3±2.6 |
0.62 0.26 0.88 |
|
Retrieved oocytes -Total -Metaphase II stage -Metaphase I stage -Germinal vesicle stage |
9.3±6.8 6.6±5.0 1.2±1.7 0.8±1.1 |
9.4±6.1 6.7±4.6 1.2±1.6 0.8±1.2 |
9.2±7.7 6.4±5.6 1.3±1.9 0.7±1.0 |
0.48 0.36 0.74 0.95 |